title: Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.
abstract: Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention. This resistance is one of the key determinants of efficacy in targeted anti-cancer drug therapy. Although poorly understood, drug resistance is already being addressed in combination therapy by selecting drug targets where SN sensitivity increases due to combination components or as a result of de novo or acquired mutations. Additionally, successive drug combinations have shown low resistance potential. To promote a rational, systematic development of combination therapies, it is necessary to establish the underlying mechanisms that drive the advantages of combination therapies, and design methods to determine drug targets for combination regimens. Based on a joint systems analysis of cellular SN response and its sensitivity to drug action and oncogenic mutations, we describe an in silico method to analyze the targets of drug combinations. Our method explores mechanisms of sensitizing the SN through a combination of two drugs targeting vertical signaling pathways. We propose a paradigm of SN response customization by one drug to both maximize the effect of another drug in combination and promote a robust therapeutic response against oncogenic mutations. The method was applied to customize the response of the ErbB/PI3K/PTEN/AKT pathway by combination of drugs targeting HER2 receptors and proteins in the down-stream pathway. The results of a computational experiment showed that the modification of the SN response from hyperbolic to smooth sigmoid response by manipulation of two drugs in combination leads to greater robustness in therapeutic response against oncogenic mutations determining cancer heterogeneity. The application of this method in drug combination co-development suggests a combined evaluation of inhibition effects together with the capability of drug combinations to suppress resistance mechanisms before they become clinically manifest.
authors.affiliation: Centre for Research in Informatics and Systems Pathology (CRISP), University of Abertay Dundee , Dundee , UK.
authors.forename: Alexey
authors.initials: A
authors.lastname: Goltsov
authors.affiliation: Division of Pathology, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh , Edinburgh , UK.
authors.forename: Simon P
authors.initials: SP
authors.lastname: Langdon
authors.affiliation: Touch Surgery , London , UK.
authors.forename: Gregory
authors.initials: G
authors.lastname: Goltsov
authors.affiliation: School of Medicine, University of St Andrews , St Andrews , UK.
authors.forename: David J
authors.initials: DJ
authors.lastname: Harrison
authors.affiliation: Centre for Research in Informatics and Systems Pathology (CRISP), University of Abertay Dundee , Dundee , UK.
authors.forename: James
authors.initials: J
authors.lastname: Bown
keywords: PI3K/PTEN/AKT; anti-cancer combination therapy; cancer drug resistance; pathway engineering; pertuzumab; signaling networks